Marinus Pharmaceuticals is a pharmaceutical company known for developing ganaxolone (brand name ZTALMY), a neuroactive steroid and GABA-A receptor modulator approved for the treatment of seizures associated with CDKL5 deficiency disorder (CDD). The company operated in the rare-disease and epilepsy space of the life-sciences industry. - View it on GitHub